Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT Study of Vicadrostat in Healthy Subjects
NCT07513207Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vicadrostat in chronic kidney disease (CKD) and heart failure (HF) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Maximum mean difference between vicadrostat and placebo in QTcF changes from baseline at 24 hours. Started Apr 2026; status: completed.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)heart failure (HF)
Beyond the preview
Go deeper on NCT07513207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513207.